Xval-OD 250 Tablet contains Divalproex sodium 250 mg, an anticonvulsant and mood-stabilizing agent primarily used in the management of epilepsy, bipolar disorder, and migraine prophylaxis. Divalproex acts by increasing brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, thereby stabilizing neuronal activity and preventing seizure propagation. This extended-release formulation ensures a steady plasma concentration, improving patient compliance and minimizing peak-related side effects. Indicated for the treatment of generalized and partial seizures, Xval-OD 250 is also effective in acute manic episodes associated with bipolar disorder and in reducing the frequency of migraine headaches. Dosage should be individualized based on clinical response and serum valproate levels, with careful titration to minimize adverse effects such as gastrointestinal disturbances, hepatotoxicity, thrombocytopenia, and weight gain. Regular monitoring of liver function tests, complete blood counts, and serum drug levels is recommended during therapy. Use in pregnancy is contraindicated due to teratogenic risk. Patients should be advised to avoid abrupt discontinuation to prevent seizure exacerbation. Xval-OD 250 Tablet should be used under strict medical supervision, considering potential drug interactions and contraindications to optimize therapeutic outcomes and ensure patient safety.